Stoke Therapeutics (STOK) Price & Analysis

Compare

400 Followers

STOK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.35 - $16.15

Previous CloseN/A

Volume337.58K

Average Volume (3M)549.50K

Market Cap

$641.51M

Enterprise Value$366.70M

Total Cash (Recent Filing)$357.32M

Total Debt (Recent Filing)$2.35M

Price to Earnings (P/E)15.1

Beta1.93

Next Earnings

Aug 11, 2025

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.90

Shares Outstanding54,596,924

10 Day Avg. Volume448,958

30 Day Avg. Volume549,501

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)1.93

Price to Sales (P/S)0.00

P/FCF Ratio9.21

Enterprise Value/Market Cap0.57

Enterprise Value/Revenue1.41

Enterprise Value/Gross Profit1.95

Enterprise Value/Ebitda-1.27

Forecast

1Y Price Target

$27.20

Price Target Upside120.24% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Stoke Therapeutics News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe zorevunersen pivotal Phase 3 EMPEROR trial in Dravet Syndrome has recently opened for enrollment, suggesting progress in clinical development.

Financial StabilitySTOK has a cash runway into mid-28, which extends past the timeline when the company expects to report pivotal EMPEROR trial data.

Market DifferentiationInclusion of positive behavioral and cognitive benefit data on the label can help differentiate zorevunersen from currently available seizure reduction drugs that do not help with cognition or behavior.

Bears Say

CompetitionCurrently no SOCs have been shown to have any impact on cognition or intellectual ability of DS patients.

Regulatory RiskIf the results are replicated in Phase 3, they could pave the way for final regulatory approval.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

39.04% Insiders

15.04% Mutual Funds

0.99% Other Institutional Investors

33.79% Public Companies and Individual Investors

Detailed Ownership Overview >

STOK FAQ

What was Stoke Therapeutics Inc’s price range in the past 12 months?

Stoke Therapeutics Inc lowest stock price was $5.35 and its highest was $16.15 in the past 12 months.

What is Stoke Therapeutics Inc’s market cap?

Stoke Therapeutics Inc’s market cap is $641.51M.

When is Stoke Therapeutics Inc’s upcoming earnings report date?

Stoke Therapeutics Inc’s upcoming earnings report date is Aug 11, 2025 which is in 24 days.

How were Stoke Therapeutics Inc’s earnings last quarter?

Stoke Therapeutics Inc released its earnings results on May 13, 2025. The company reported $1.9 earnings per share for the quarter, beating the consensus estimate of $0.109 by $1.791.

Is Stoke Therapeutics Inc overvalued?

According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Stoke Therapeutics Inc pay dividends?

Stoke Therapeutics Inc does not currently pay dividends.

What is Stoke Therapeutics Inc’s EPS estimate?

Stoke Therapeutics Inc’s EPS estimate is -0.5.

How many shares outstanding does Stoke Therapeutics Inc have?

Stoke Therapeutics Inc has 54,596,924 shares outstanding.

What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?

Stoke Therapeutics Inc reported an EPS of $1.9 in its last earnings report, beating expectations of $0.109. Following the earnings report the stock price went down -7.557%.

Which hedge fund is a major shareholder of Stoke Therapeutics Inc?

Currently, no hedge funds are holding shares in STOK

Stoke Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

20.50%

Trailing 12-Months

Asset Growth

98.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Stoke Therapeutics Inc

Stoke Therapeutics (STOK) is a biotechnology company focused on pioneering RNA-based medicines to treat severe genetic diseases. Operating within the healthcare and biotechnology sectors, the company specializes in developing treatments for conditions caused by genetic mutations with a focus on precision medicine. Its core product is the proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which is designed to selectively increase protein production to achieve therapeutic benefits.

STOK Stock 12 Month Forecast

Average Price Target

$27.20

▲(120.24%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","36":"$36","12.75":"$12.75","20.5":"$20.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.75,20.5,28.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,13.446153846153846,15.242307692307692,17.03846153846154,18.834615384615386,20.630769230769232,22.426923076923078,24.223076923076924,26.01923076923077,27.815384615384616,29.611538461538466,31.407692307692308,33.20384615384616,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,12.846153846153847,14.042307692307693,15.23846153846154,16.434615384615384,17.630769230769232,18.826923076923077,20.02307692307692,21.21923076923077,22.415384615384617,23.611538461538462,24.807692307692307,26.003846153846155,{"y":27.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,12.292307692307693,12.934615384615384,13.576923076923077,14.21923076923077,14.861538461538462,15.503846153846155,16.146153846153844,16.78846153846154,17.43076923076923,18.073076923076922,18.715384615384615,19.357692307692307,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.87,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >